Drug Trial Radar · NCT04714294
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Jan 19, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
84
Planned (sponsor's estimate)
Start
Sep 8, 2020
Primary completion
May 31, 2021
Study completion May 31, 2021
Sponsor
- Lead sponsor
- Newsoara Biopharma Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 19, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Chronic obstructive pulmonary disease (COPD) is a common, preventable and treatable disease characterized by persistent respiratory symptoms and incompletely reversible airflow limitation. It is usually caused by airway and / or alveolar abnormalities caused by obvious exposure to toxic particles or gases.COPD is currently the fourth leading cause of death in the world, and is expected to be the third leading cause of death by 2020.HPP737 as an oral PDE4 inhibitor for the treatment of COPD.Preclinical data showed that the activity of HPP737 was similar to that of rofloxacin, but HPP737 significantly reduced the permeability to CNS and may have better tolerance. HPP737 will be used to develop indications for chronic obstructive pulmonary disease, and PK study in Chinese people is going to to evaluate the safety and tolerability of HPP737 in healthy volunteers.
Conditions
- Healthy
Interventions
HPP737 or placeboDrug
HPP737 or placebo will be randomized to assign to subjects
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluate changes of Safety and tolerability from day 1 to day 7 (SAD) or day 14(MAD)Time frame: SAD: from the screening period to the 7th day; MAD: from the screening period to the 14th day;
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Affiliated Hangzhou First People's Hospital.Zhejiang University School of Medicine
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.